Dr. Kun Meng is a co-founder, Chairman & CEO of Shenogen Pharma Group. He has more than 15-year research experience in molecular biology, small molecule drug and pharmacology, as well as over 10-year experience of drug development and management in pharma industry. He is familiar with the overall process of drug R&D ranging from research to clinic, from market to venture. He also stays in touch with the latest progress in biopharma domestic and abroad. He maintains a broad network with researchers, industrialists, entrepreneurs and investors. Dr. Meng was CEO of a traditional Chinese medicine technology company and Chief Technical Officer of Jianxin Pharmaceuticals Co., Ltd. Dr. Meng 

    Board of Directors

received Ph.D. degree of Biochemistry from Chinese Academy of Sciences. He completed postdoctoral training from Harvard and Washington University School of Medicine, and he also received MPA degree from Kennedy School at Harvard. Dr. Meng was elected to the National Thousand Talents, Beijing High-level Talents Organization and Beijing Scientific Leader Program.

Dr. Charlie Wang is a co-founder, Chief Science Officer & Member of Board of Directors of Shenogen Pharma Group. He received Ph.D. degree from Washington University at St. Louis. He completed postdoctoral training in Princeton University, and was Assistant Professor of Harvard Medical School. Dr. Wang was a professor of pathology in Creighton University, director of an oncology laboratory when he founded Shenogen together with Dr. Kun Meng. Dr. Wang has over 20-year experience in cancer research. He is expert in molecular cancer biology, especially cell proliferation, differentiation and apoptosis. Dr. Wang is dedicated to study breast cancer related genes. He identified and cloned a novel membrane 

estrogen receptor ER-alpha 36 and studied its functions. His findings greatly contributed to the understanding of the pathogenesis of breast cancer, and got high remarks from Elwood Jensen, fellow of National Academy of Sciences and V. Craig Jordan, “Father of Tamoxifen”. Dr. Wang received grants from NIH, American Cancer Society, the US Department of Defense and Susan G. Komen Foundation. Dr. Wang has authored/ co-authored more than 70 peer-reviewed papers, host and attended many key scientific conferences, written four books and owned three granted patents. Dr. Wang returned China in 2014. He was elected into the Recruitment Program of Global Experts, Beijing Haiju Program and Shandong Taishan Academician Program.

Dr. Jun Bao is Senior Vice President and Chief Business Officer of Shenogen Pharma Group. He also serves as a member of board of directors as well as acting Chief Financial Officer. He is responsible for company’s business development, financing and corporate strategy. He has over 20 years of combined business and science experiences. He is well-experienced in the areas of new drug R&D, technology transfer, licensing and business development, venture investment and corporate financing. Before he joined Shenogen, Dr. Bao was Director, Worldwide Business Development, Head of China at GlaxoSmithKline (GSK), responsible for business development activities in China. Prior to GSK, he worked at Onyx Pharmaceuticals, ICOS Corporation and Cell Therapeutics as a business development executive 

with progressive responsibilities. Dr. Bao also worked as a finamanager in Procter & Gamble based in Cincinnati. He received a BS in Microbiology from Shandong University and a PhD in Neuroscience from University of Kansas. Dr. Bao completed his postdoctoral fellowship in Johns Hopkins University. In addition, he received an MBA in Finance from University of Chicago. He has authored/co-authored more than 30 research publications and co-founded two start-up biotech companies. Dr. Bao was also a board member of BayHelix.

Dr. Larry Zhang is Chief Operation Officer and Chief Technology Officer of Shenogen Pharma Group. He graduated from Fudan University School of Chemistry and received Ph.D. of Organic Chemistry in University of Pittsburgh. He completed postdoctoral training in Duke University. After that, Dr. Zhang served in Gilead Science as Scientist, Senior Scientist and Project Manager in turn. He was a professor in Shanghai Jiaotong University School of Pharmacy and Chief Science Officer of Tsinghua Yuanxing biopharma company. Dr. Zhang was elected as a fellow of the American Chemistry Society. He is currently the director of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences. Dr. Zhang has 20-year experience in designing, synthesizing and developing of reverse translational drug, small molecule anti-virus RNA drug and anti-cancer drug. He was responsible for the R&D and amplification of 

generic drug of Oseltamivir in China, with the brand name Tamiflu. This work is a good preparation for new generation NA Oseltamivir drug R&D. He also successfully transferred the synthesis process of anti-influenza drug Zanamivir to Chia Tai Tianqing (Jiangsu), making it mutual beneficial to both the enterprise and the institute. Dr. Wang published 39 papers, including 32 SCI, and applied for 20 patents. 

Mr. Jianguang Li,IDG Capital Partner, has extensive experience in finance. In 1999, he was director assistant of Tinhtic Trust & Investment, in charge of investment banking and direct investment business. From 1994 to 1999, Mr. Li was director of Crosby Beijing Branch, responsible for projects supervision and developing. He raised 37 million dollar direct investment for China Investment Co. Ltd to be listed on the London Stock Exchange. At the same time, Mr. Li is also responsible for acquisition and merger business of pulp, paper and packaging companies both domestic and abroad. He had evaluated on hundreds of investment projects, cooperated widely with state-owned, collective, private and foreign enterprises, with extensive experience in investment evaluation, organization and management in China. From 1987 to 

1992, Mr. Li served as researcher of Chinese Academy of Social Science. He graduated from Peking University majoring in Economy in 1987, and earned Master of Applied Economics and Enterprise Management in Guelph University. 

Mr. Lei Chen, Funding Partner of TusPark Ventures, focuses investment on biopharma, healthcare and new material. He has rich experience and resource in IVD, cancer drugs, medical devices, CRO, CMO and medical informatics. Mr. Chen joined TusPark Ventures in 2005 and served as investment manager, senior investment manager and chief investment officer in turn. He was independently responsible for investment and management of eleven companies, including Crownbio, ACCB, Shenogen and others. Mr. Chen received his B.S and M.S in Tsinghua University, School of Material Science. 

Mr. Daqing Cai is Executive Director of Legend Capital. He joined Lenovo Capital, predecessor of Legend Capital, as chief investment officer in May, 2011. Mr. Cai focuses on the field of healthcare investment, led projects including Berrygenomics, Bioustar, Shenogen, Cardea and Axonics. Before Legend Capital, he was Managing Director of SBI Group and SBI-BDJB Investment. He also has leader experiences in Sinochem (HK) and Booz Allen Hamilton, and was Director & CFO in BGI. Mr. Cai received Ph.D. from University of California-Berkeley, MBA from Yale University and B.S. from University of Science and Technology of China.

Nisa Leung is a Managing Partner of Qiming Ventures leading its health care investments. Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals Inc (acquired by SciClone NASDAQ: SCLN), a specialty pharmaceutical company focused on oncology and central nervous system and U-Systems Inc (acquired by GE Healthcare).  Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital. Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She currently serves on the Board of Governors of the Hotchkiss School, is member of Cornell Life Sciences Advisory Board, director of Young Entrepreneur Development Council and director of Hong Kong Science and Technology Parks Corporation.